SEP 11, 2018 10:43 PM PDT

Stimuli-Responsive Nanoparticles as a Drug Delivery Method

WRITTEN BY: Nouran Amin

Image Credit: Phys.Org

Researchers at Washington State University (WSU), who were finding a way to fight an inflammatory response that causes organ failure better known as sepsis, show that stimuli-responsive nanoparticles can target infections to simultaneously inhibit the spread of bacteria and decrease inflammation. Such microscopic particles include abundant antibiotic and anti-inflammatory agents that are released when the particles encounter an infection in the body.

"This study not only proves a new drug delivery system but also may shift the current landscape in nanomedicine to a biology-driven design of nanotherapeutics. This has the potential to improve the therapies of many more infectious diseases," explains Zhenjia Wang, a pharmaceutical sciences professor.

The research study, published in the journal Advanced Materials, shows how WSU scientists developed a new nanoparticle that is coated with compounds that are commonly secreted by blood vessels in response to an infection. The nanoparticle is sensitive to infections sites allowing the bacterial enzymes to be triggered for the release of drugs.

Image Credit: Structure of a nanoparticle via Kaust.edu

Although with antibiotics and anti-inflammatories are used to mitigate the onset of sepsis, there remain issues with “old school use of these therapies”. "This study will allow chemists and materials engineers to design new drug formulations to treat many bacterial infections, such as TB infection," explains Can Yang Zhang, who is the leading author on the paper and a postdoctoral research associate in the Wang lab.

In medicine, nanoparticle technology is growing, however, it is a first time that a nanocarrier has been developed to deliver not one, but two drugs. Furthermore, nanocarrier specifically targets infection sites, so less medicine may be a needed to fix collateral damage to otherwise healthy tissues.

Source: Washington State University

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
SEP 29, 2020
Drug Discovery & Development
Cycling Molecules into Drug Candidates
SEP 29, 2020
Cycling Molecules into Drug Candidates
Statistics show that just 1 in 5,000 drug candidates ever makes it from the lab to the pharmacy. In a process that can t ...
OCT 06, 2020
Cardiology
A New Heart Drug Taken from a Yellow Dye
OCT 06, 2020
A New Heart Drug Taken from a Yellow Dye
Cardiovascular disease is an ever-present issue in the modern world.  One of the most unfortunate cardiovascular ev ...
OCT 21, 2020
Drug Discovery & Development
Experimental Vaccine Shows Promise in Halting Alzheimer's
OCT 21, 2020
Experimental Vaccine Shows Promise in Halting Alzheimer's
In a preclinical study, researchers from the Univerity of South Florida have found that a vaccine that targets neurotoxi ...
OCT 07, 2020
Technology
Millimeter-Precision Drug Delivery
OCT 07, 2020
Millimeter-Precision Drug Delivery
It is almost impossible to deliver targeted drug therapy via the bloodstream without reaching the entire brain and body ...
NOV 11, 2020
Cancer
A New CDK Inhibitor Could Help with Unresponsive Liver Cancer
NOV 11, 2020
A New CDK Inhibitor Could Help with Unresponsive Liver Cancer
Amongst the most common targets of anti-cancer drugs are small regulatory molecules called cyclin-dependent kinases (CDK ...
NOV 26, 2020
Cardiology
Possible Cardioprotective Effects of the Diabetes Drug Empagliflozin
NOV 26, 2020
Possible Cardioprotective Effects of the Diabetes Drug Empagliflozin
Cardiovascular disease and diabetes are often associated with each other, as many issues caused by diabetes promote hear ...
Loading Comments...